Published in Medical Letter on the CDC and FDA, March 5th, 2006
The results of the phase I safety and immunogenicity dose-escalation study indicate the vaccine is well-tolerated and induces antibodies in humans that neutralize ricin toxin. The outcome of the study was to be published in the online edition of the Proceedings of the [U.S.] National Academy of Sciences.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA